Part 4 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment features a newly developed therapeutic option in the treatment of heart disease.

Part 3 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment explores the development of cardiovascular disease at the physiological level, and explains the connection between energy homeostasis and the progression of atherosclerosis.

Part 2 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment highlights the mechanisms and effects of metabolic energy imbalances on the development of heart failure.

Part 1 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment gives an overview of the two major cell glucose transporter families - GLUTs and SGLTs - and explains their individual locations, functions, and potential as therapeutic targets.

MOA animation featuring a groundbreaking new drug developed for heart disease. This animation visually explains the multi-faceted molecular mechanisms that underlie the drug's significant CV risk reductions.

Scientific animation visualizing the membrane dynamics of omega-3 fatty acids EPA and DHA, as well as their respective effects on lipid peroxidation and cholesterol domain formation.